Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

TORONTO, July 21 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (Lorus), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three and twelve months ended May 31, 2008. Unless specified otherwise, all amounts are in Canadian dollars.

2008 HIGHLIGHTS

- Initiation of GLP toxicology studies for Lorus' lead anticancer small

molecule drug LOR-253. The toxicology studies, currently underway,

are designed to support the filing of an Investigational New Drug

(IND) application with the U.S. FDA for LOR-253 to initiate a Phase I

clinical study in cancer indications. Lorus intends to submit an IND

for LOR-253 by the Q4/2008 or 1Q/2009, following successful

completion of the toxicology program in the third quarter of 2008

calendar year.

- Announced completion of a proof-of-concept clinical trial in Acute

Myeloid Leukemia (AML), and expansion of its LOR-2040 development

program in this indication, with initiation of a more advanced

Phase II clinical trial. The proof-of-concept study generated

encouraging results demonstrating safety and appropriate dosing of

the combination regimen. Notably, promising clinical responses in

patients under 60 years of age were obtained which included complete

responses in 35% of the 23 patients and significant cytoreduction of

leukemic blasts in two others. Moreover, the clinical responses

correlated with downregulation of R2, the cellular target of LOR-

2040, and were further supported by demonstration of intracellular

LOR-2040 in circulating and bone marrow leukemic cells.

- Signed an exclusive multinational license agreement with Zor

Pharmaceuticals LLC ("ZOR") formed as a subs
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Ind. -- Chemists at Indiana University Bloomington have ... bricks-and-mortar fashion, a development with potential value for ... field-effect transistors and photovoltaic cells. , Their paper, ... Crystalline Solids and 2D Self-Assembled Crystals," has been ... journal of the Royal Society of Chemistry. It ...
(Date:7/31/2014)... July 31, 2014 Rogne Bioscience, a privately-held ... Area , has acquired a licence to anti-inflammatory ... company. The potent anti-inflammatory activity of the peptides was ... University of Oxford,s Sir William Dunn School ... raised over $1.5 million in seed financing, is developing ...
(Date:7/31/2014)... York , July 31, 2014 ... Transparency Market Research "Electrodes for Medical Devices Market (Diagnostic ... Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and ... Trends and Forecast, 2013 - 2019," the global electrodes ... million in 2012 and is estimated to reach a ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Company recently expressed concern to Department of Health and ... impede clinical research trials. , ,Institutional review boards are ... patient authorizations for use and disclosure of information, according ... of Indianapolis-based Eli Lilly. , ,In a response ...
... a dying breath, HTML-based email messages find themselves glimpsing a ... email messages are becoming more popular, and more successful, than ... Marketing survey indicated that 53% of AOL respondents ... Although theyve conducted this survey before, this is the first ...
... an emergency room management application that includes a ... said Dr. Seth Foldy, the city's health commissioner. ... by the Frontlines of Medicine Project , ... specialists that is marketed by Infinity HealthCare Inc.'s ...
Cached Biology Technology:Style Without Substance: Will HTML Email Survive Abuse? 2
(Date:7/31/2014)... Dr. Oren Tessler, Assistant Professor of Clinical Surgery ... Medicine, is part of a team of plastic and ... a method to screen and select patients for a ... the patients who underwent this surgery to decompress the ... a bonus cosmetic eyelid surgery. The study, which confirms ...
(Date:7/31/2014)... 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric authentication ... investors and consumers wanting to learn more about ... be on-air today, July 31 st . ... be featured in a segment of NewsWatch, a ... on the History Channel, FYI Network today. ...
(Date:7/30/2014)... Carroll,s Through the Looking Glass, collaborators from the ... improved a 35-year-old ecology model to better understand ... years. , The new model, called a mean ... Effect," an evolutionary hypothesis introduced by Lee Van ... must constantly increase their fitness (or ability to ...
Breaking Biology News(10 mins):Surgeons report significant migraine relief from cosmetic eyelid surgery technique 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 2NXT-ID's Next Generation Biometric Smart Wallet Featured on NewsWatch Consumer Show on the History Channel and FYI Network Today, July 31st 3Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... summer brings trips to the lake, afternoons at the beach ... threat of dangerous conditions in closed cars, where children left ... Now, a team of researchers at the University of ... that may help public officials and media remind the public ...
... in Orissa State, India, increased treatment compliance from ... a study published June 29 in the open-access ... their study, researchers from the U.S. Centers for ... Church,s Auxiliary for Social Action, an India-based non-governmental ...
... June 2010) -- The U.S. Supreme Court ruled 5-4 Monday ... and that the ability to patent software should not be ... that passing the "machine or transformation" test is not the ... Abstract ideas, however, cannot be patented. IEEE-USA was party ...
Cached Biology News:New UGA temperature table may help reduce heat-related deaths of children in closed cars 2New UGA temperature table may help reduce heat-related deaths of children in closed cars 3Community-based education strengthens campaign for elimination of lymphatic filariasis 2
...
... pWEB::TNC™ Deletion Cosmid Cloning Kit enables you ... complete and unbiased primary cosmid library of ... nested deletion sublibraries. High efficiency cosmid library ... reproducible kit protocols. First, genomic DNA is ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
... is a revolutionary multi-capillary electrophoresis system which ... It integrates sample loading, electrophoresis, and data ... the workflow and increasing the productivity of ... of using HDA system are:, No ...
Biology Products: